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ABSTRACT
Microvesicles (MVs) play a pivotal role in cell-to-cell com-
munication. Recent studies demonstrated that MVs may
transfer genetic information between cells. Here, we show
that MVs derived from human adult liver stem cells
(HLSC) may reprogram in vitro HepG2 hepatoma and pri-
mary hepatocellular carcinoma cells by inhibiting their
growth and survival. In vivo intratumor administration of
MVs induced regression of ectopic tumors developed in
SCID mice. We suggest that the mechanism of action is
related to the delivery of microRNAs (miRNAs) from
HLSC-derived MVs (MV-HLSC) to tumor cells on the basis
of the following evidence: (a) the rapid, CD29-mediated
internalization of MV-HLSC in HepG2 and the inhibition
of tumor cell growth after MV uptake; (b) the transfer by
MV-HLSC of miRNAs with potential antitumor activity
that was downregulated in HepG2 cells with respect to nor-
mal hepatocytes; (c) the abrogation of the MV-HLSC anti-
tumor effect after MV pretreatment with RNase or
generation of MVs depleted of miRNAs; (d) the relevance
of selected miRNAs was proven by transfecting HepG2
with miRNA mimics. The antitumor effect of MV-HLSC
was also observed in tumors other than liver such as lym-
phoblastoma and glioblastoma. These results suggest that
the delivery of selected miRNAs by MVs derived from stem
cells may inhibit tumor growth and stimulate apoptosis.
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INTRODUCTION
Several studies suggest that the embryonic microenvironment
may favor reprogramming of tumor cells toward a more
benign phenotype [1, 2]. Whether adult stem cells may also
have the capability to reprogram the tumor phenotype remains
controversial. Bone marrow-derived mesenchymal stem cells
(MSCs) were shown under certain circumstances to inhibit
tumor growth in a model of Kaposi’s sarcoma [3] and of hep-
atoma [4, 5]. On the other hand, MSC may favor tumor
escape by inducing immunosuppression [6, 7].
We recently identified a multipotent human adult liver
stem cell (HLSC) population that expresses mesenchymal and
embryonic stem cells markers and is partially committed to
the hepatic lineage [8, 9]. Microvesicle (MV)-HLSC were
found to transfer genetic information to target cells [9, 10].
MVs include a heterogeneous population of vesicles released
as exosomes from the endosomal compartment or as shedding
vesicles from the cell surface of different cell types [11–13].
It is now recognized that MVs constitute an integral part of
the intercellular microenvironment [12, 14, 15]. The broad
spectrum of biological activities displayed by MVs candidate
them to a pivotal role in cell-to-cell communication. This
notion is based on the observation that MVs released from a
given cell type may interact through specific receptor–ligand
with target cells. After interaction, MVs may directly stimu-
late the target cells or may transfer various bioactive mole-
cules including mRNAs and microRNAs (miRNAs) from the
cell of origin [16–20]. Recently, Balaj et al. [21] found that
tumor MVs contain also retrotransposon elements and ampli-
fied oncogene sequences. Therefore, MVs may induce epige-
netic changes in target cells by delivering specific genetic
information. Ratajczak et al. [22] demonstrated that MVs
derived from murine embryonic stem cells may reprogram
adult hematopoietic stem/progenitor cells. We found that
MVs derived from human endothelial progenitors, MSCs, or
HLSC can act as a vehicle for exchange of functional mRNAs
among cells leading to activation of regenerative programs in
differentiated cells both in vitro and in vivo [23, 24, 9].
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Valadi et al. [25] showed that exosomes released from mast
cells contained specific subset of miRNAs. Yuan et al. [26]
demonstrated that miRNAs may be transferred from embry-
onic stem cells to mouse embryonic fibroblasts via MVs. We
recently characterized miRNAs shuttled by HLSC-derived
MVs (MV-HLSC) showing that they may potentially affect
development, cell fate, differentiation, catalytic activities, and
metabolic processes [10].
The aim of this study was to investigate whether MV-
HLSC may influence the growth of a hepatoma both in vitro
and in vivo. We evaluated in vitro the effect of MVs on cell
proliferation and apoptosis resistance of HepG2 hepatoma cell
line and of four hepatocellular carcinoma cell (HCC) lines. In
vivo, we evaluated whether MV-HLSC induced the tumor
regression in an ectopic model of transplantation in SCID
mice. In addition, by silencing Dicer in HLSC or using
selected miRNA inhibitors, we evaluated the role of miRNAs,
shuttled by MV-HLSC, in the suppression of tumor growth.
MATERIALS AND METHODS
Cells
HLSC were isolated from human cryopreserved normal hepato-
cytes obtained from Lonza (Basel, Switzerland, www.lonza.com),
characterized and cultured as previously described [8]. Normal
human hepatocytes and human fibroblasts (Lonza) were cultured
as described [9, 24]. Hepatoma cell line HepG2 (American Type
Culture Collection, Rockville, MD, www.atcc.org) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum (FBS). Primary hepatoma cell lines were
generated in our laboratory from tumor specimens of four patients
with histopathological diagnosis of HCC undergoing surgical
resection with informed consent at the Liver Transplantation Cen-
ter of Molinette Hospital, Turin. HCC cells were cultured in
DMEM, 10% FBS and characterized by immunohistochemistry
for the expression of a-fetoprotein, heat shock protein 70, cyto-
keratin 19, 8, and 18 [27, 28]. Glioblastoma cell line DBTRG
(kindly provided by Dr. Oliviero) and T lymphoblastic tumor cell
line SupT1 (kindly provided by Dr. Tarella) were cultured in
Roswell Park Memorial Institute (RPMI)-1640, 10% FBS, and
GlutaMAX (Life Technologies, New York, NY, http://
www.lifetech.com).
Generation of Dicer1 Knockdown HLSC
The knockdown of Dicer was obtained by transfecting HLSC
with a Dicer1 shRNA plasmid (DCR-kd HLSC) (sc-40489-SH,
Santa Cruz Biotechnology, Santa Cruz, CA, http://www.scbt.com)
using lipofectamine (Life Technologies). HLSC transfection with
a plasmid coding for a scramble short hairpin RNA (shRNA)
sequence was used as control (CTR-A HLSC). Cells were grown
in the presence of 1 lg/ml puromycin to select stably transfected
HLSC that were tested for Dicer expression. Transfected HLSC
were used until sixth passage of culture.
Cell Transfection
Transfection of miScript miRNA Inhibitors and Mimics to
HepG2 was performed using the HiPerFect Transfection method
(Qiagen, Valencia, CA, http://www.qiagen.com) according to the
manufacturer’s protocol.
For HepG2 transfection (8  103 cells), 10 nM mimics or
100 nM miScript miRNA inhibitors along with 1 ll HiPerFect
Transfection Reagent (all from Qiagen) were used. The day after
transfection, HepG2 were cultured in their complete medium (for
mimics) or in the presence of 30 lg/ml of MV-HLSC (for
miRNA inhibitors) for 72 hours. AllStars negative control siRNA
(SCR) or miScript Inhibitor negative control (anti-CTR) were
used as controls.
For fibroblast transfection, pCMV-Sport six plasmid carrying
the human integrin, b1 (CD29) full-length cDNA sequence was
purchased from Open Biosystems (Lafayette, CO, www.openbio-
systems.com). Subconfluent fibroblasts (6  105 cells per 100
microliters) were harvested and resuspended in Nucleofector Solu-
tion (Lonza). Nucleofection was performed by mixing the cell sus-
pension (100 ll) with the plasmid (6 lg) using the Nucleofector
device (Amaxa) and the preoptimized program (U-23). Immedi-
ately following nucleofection, the cells were plated in their com-
plete cultured medium. Nucleofection of fibroblasts in the absence
of DNA was used as negative control (fibr-CTR). Control
pmaxGFP vector (Amaxa) was used as transfection efficiency con-
trol. The day after transfection, fibroblasts were cultured overnight
in serum-free medium to collect MVs. Cells and MVs were then
used for RNA and protein isolation and for the in vitro assays.
Isolation of MVs
MVs were obtained from supernatants of HLSC cultured over-
night in a-Minimum Essential Medium (MEM) with 2% of MV-
depleted FBS by differential centrifugation and ultracentrifugation
at 100,000g as previously described [23]. MVs were also isolated
from fibroblasts as previously described [24]. To trace MVs,
HLSC were labeled with SYTO RNASelect green fluorescent cell
stain (Life technologies), MVs were then collected and labeled
with PKH26 dye (Sigma, St. Louis, MO, www.sigmaaldrich.com)
[23]. Fluorescence-activated cell sorting (FACS) analysis on MVs
was performed as previously described [9].
In selected experiments, MV-HLSC were treated with 5 U/ml
RNase (Life technologies) for 3 hours at 37C; the reaction was
stopped by addition of RNase inhibitor (Life Technologies) and
MVs were washed by ultracentrifugation. Size and distribution of
MV after RNase treatment were evaluated by nanoparticle track-
ing analysis (NTA) using NanoSight LM10 instrument (Nano-
Sight Ltd., Amesbuty, U.K., www.nanosight.com) equipped with
the NTA 2.0 analytic software [29]. RNase did not affect surface
and protein expression of MV as previously reported [24].
RNA Extraction and Quantitative Real Time
Reverse Transcriptase Polymerase Chain Reaction
Total RNA was isolated using the mirVana RNA isolation kit
(Life Technologies), quantified spectrophotometrically (Nanodrop
ND-1000, Wilmington, DE, www.nanodrop.com) and submitted
to capillary electrophoresis on Agilent 2100 bioanalyzer (Agilent
Tech. Inc., Santa Clara, CA, www.agilent.com). Quantitative
reverse transcriptase polymerase chain reaction (qRT-PCR) for
gene expression analysis was performed as previously described
[30]. Sequence-specific oligonucleotide primers used (MWG-Bio-
tech AG, Ebersberg, Germany, www.mwg-biotech.com) were lis-
tened in Supporting Information Table 1.
miRNA expression was analyzed using the miScript Reverse
Transcription Kit and miScript SYBR Green PCR Kit (Qiagen)
on a 48-well StepOne Real Time System (Life Technologies) as
previously described [10]. miRNA-specific primers to hsa-miR-
451, -223, -24, -125b, -31, -21, -122, -16-1, and -410 were used
in separate reactions. The RNU48 small nucleolar RNA was used
as control. miRNA and mRNA comparison between samples was
calculated on relative expression data normalized using GAPDH
and 18S, as endogenous controls. Fold change expression with
respect to controls was calculated for all samples.
For RNase-treated MVs, fold change in miRNA expression
was calculated based on cycle threshold (Ct) differences between
treated and untreated MVs (2(DCt)) loading the same quantity of
RNA during the reverse transcription procedure.
Incorporation of MVs in Cancer Cells and
miRNA Transfer
Incorporation of MVs into tumor cell lines was evaluated by
FACS analyses and confocal microscopy after incubation with 50
lg/ml of PKH-26-labeled MVs for 1 hour at 37C. In selected
experiments, MVs were preincubated with blocking antibodies
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(1 lg/ml) anti-a4 integrin, -a6 integrin (Biolegend, San Diego,
CA, www.biolegend.com), anti-CD44 and anti-CD29 (BD Phar-
mingen, San Jose, CA, www.bdbiosciences.com) to inhibit MV
incorporation by target cells.
To analyze miRNA transfer from MVs, HepG2 (6  105 cells
per well) were preplated in a 65 cm2 Petri dish and stimulated
with 30 lg/ml of MV-HLSC. Cells were coincubated with MVs
and a transcription inhibitor, a-amanitin (Sigma, 50 lg/ml) or with
a-amanitin alone [31] to inhibit transcriptional activation induced
by MVs. miRNA transfer to HepG2 was analyzed by qRT-PCR, at
different time points (6, 16, and 24 hours) as previously described
[10]. The difference in Ct values between a-amanitin-treated cells
in the absence and in the presence of MVs at each experimental
time point was measured; a positive value indicated transfer.
Proliferation and Apoptosis Assays
DNA synthesis was detected as incorporation of 5-bromo-2-deox-
yuridine (BrdU) using an enzyme-linked immunosorbent assay kit
(Chemicon, Temecula, CA, http://www.chemicon.com). Apoptosis
was evaluated using the terminal dUTP nickend labeling assay
(TUNEL, ApopTag, Merck Millipore, Billerica, MA, http://
www.millipore.com). Vincristine (10 ng/ml) and doxorubicin (50
ng/ml) were used as positive control of apoptosis. The effect of
MV-HLSC on normal human hepatocytes was evaluated by treat-
ment with 5 mM D-Galactosamine (GalN), a hepatocyte-specific
apoptotic stimulus [32].
Western Blot Analysis
After cellular lysis, 100 lg of proteins (Bradford) was subjected
to 10% SDS-polyacrylamide gel electrophoresis under reducing
conditions, electroblotted onto nitrocellulose membrane filters,
and developed with enhanced chemiluminescence (ECL) detec-
tion reagents (GE Healthcare Europe GmbH, Freiburg, Germany,
www.gehealthcare.com) [10]. As primary antibodies, mouse anti-
dihydrofolate reductase (DHFR, sc-74593), anti-cyclin D1 (sc-
20044), anti-CD29 (sc-71392) and anti-Actin (sc-8432), rabbit
anti-E2 transcription factor-2 (E2F-2, sc-22821), anti-BCL-2 (sc-
783), anti-XBP-1 (sc-7160), anti-BCL-XL (sc-634), and goat anti-
Dicer (sc-25117) (Santa Cruz Biotechnology) were used. Primary
antibodies were detected using appropriate HRP-secondary anti-
bodies (Thermo Scientific, MA, www.thermoscientific.com).
Immunofluorescence
Indirect immunofluorescence of HepG2 cell line or on 5-lm par-
affin sections of HepG2 tumors was performed by staining with
the following antibodies: mouse anti-multidrug resistance protein 1
(MDR1, MAB4334, Chemicon), rabbit anti-ras-related protein 14
(RAB14, ab28639, Abcam, Cambridge, U.K., http://www. abcam.
com) and anti-E2F-2 (Santa Cruz) and goat anti-macrophage
migration inhibitory factor (MIF, AF-289-PB, R&D Systems, Min-
neapolis, MN, http://www.rndsystems.com). Paraffin sections were
subject to antigen retrieval, washed and labeled with primary anti-
bodies. Primary antibodies were then detected using appropriate
secondary antibodies, Alexa Fluor 488 or Texas Red IgG (Molecu-
lar Probes, Leiden, The Netherlands, http://probes. invitrogen.com).
Omission of the primary antibodies or substitution with nonim-
mune rabbit IgG was used as controls. Confocal microscopy was
performed using a Zeiss LSM5 Pascal confocal microscope (Carl
Zeiss Int., Oberkochen, Germany, http://www.zeiss.com). Hoechst
33258 dye (Sigma) was added for nuclear staining.
In Vivo Tumor Model
Experiments were performed in accordance with the national
guidelines and regulation and were approved by the Ethic Com-
mitting of the University of Turin. Male SCID mice (4–5 weeks
old, Charles River Laboratories, Wilmington, MA, www.criver.
com) received on day 0, an injection (3  106) of tumor cells in se-
rum-free DMEM with Matrigel at a 1:1 ratio. Cell suspension was
injected in a total volume of 0.2 ml into the left inguinal area of the
SCID mice. Treatments started when tumors reached the volume of
approximately 15 mm3. Intratumor injection of 100 lg of MVs in a
volume of 20 ll or the same volume of vehicle alone was per-
formed weekly for 3 weeks. In select experiments, the day before
MV injection, an intratumor injection of select miRNA inhibitors
(1.5 nmol/20 ll) was administrated. Tumor mass was determined
every 3 days by caliper, measurement in two perpendicular diame-
ters and calculated using the formula 1/2a  b2, where a stands for
the long diameter and b is the short diameter. Mice were sacrificed
and tumors were collected for further analysis.
Morphological Studies
Tumors were frozen in Optimum Cutting Temperature (OCT) or
fixed in 10% buffered neutral formalin. Specimens were routinely
processed, embedded in paraffin, sectioned at 5 lm, and stained
with hematoxylin and eosin (H&E) for microscopic examination.
Immunohistochemistry for detection of proliferation and apoptosis
was performed using the anti-PCNA monoclonal antibody (Santa
Cruz) or TUNEL, respectively, as previously described [9].
Statistical Analysis
All data of different experiments were expressed as mean 6 SD.
Statistical analysis was performed by ANOVA with Newmann-
Keuls multicomparison or Dunnett’s post hoc tests or by
Student’s t test as appropriate. Two-tailed p value <.05 was con-
sidered statistically significant.
RESULTS
MV-HLSC Induced In Vitro Apoptosis and
Decreased Proliferation of HepG2 Cells
We previously demonstrated that MV-HLSC expressed sev-
eral adhesion molecules also present on HLSC plasma mem-
brane such as a4 integrin, CD29, and CD44 [9]. To investigate
the role of adhesion molecules expressed on MV surface in the
incorporation into target cells, MV-HLSC were preincubated
with blocking antibodies (1 lg/ml) against a4 integrin, a6
integrin, CD29, or CD44 before the incubation with the cells.
MV-HLSC labeled with PKH26 dye were incorporated by
HepG2 after 1 hour of incubation at 37C as shown by confo-
cal microscopy and FACS analysis (Fig. 1A). Pretreatment
with anti-a4 integrin and anti-CD29 blocking antibodies inhib-
ited MV-HLSC incorporation in HepG2. Blockade of CD44
did not inhibit the incorporation of MV-HLSC in HepG2
(Fig. 1A). The anti-a6 integrin blocking antibody, used as neg-
ative control, was unable to prevent MV-HLSC internalization
in HepG2 since MV-HLSC do not express this integrin [9].
MV-HLSC inhibited proliferation (Fig. 1B) and induced
apoptosis in HepG2 and HCC cell lines in a dose-dependent
manner (Fig. 1C). On the contrary, in normal human hepato-
cytes that internalize MV-HLSC, the latter slightly stimulated
hepatocyte proliferation (Fig. 1B) and were protective in
D-galactosamine (GalN)-induced apoptosis (Fig. 1D). The
apoptotic effect induced by MV-HLSC on HepG2 was com-
parable to that of vincristine and doxorubicin used as positive
controls (Fig. 1D). When MV-HLSC were coincubated with
these chemotherapeutic agents, a significant enhancement of
apoptosis was observed (Fig. 1D). The effect of MV-HLSC
was specific since the MVs derived from fibroblasts (MV-fibr)
were ineffective (Fig. 1B, 1C). MV-fibr lack CD29 [24] and
were only slightly internalized by HepG2 (Fig. 1A). The
absence of CD29 in MVs from fibroblasts was the main cause
of reduced internalization. In fact MVs derived from trans-
fected fibroblasts overexpressing the CD29 (MV-fibr-CD29;
Supporting Information Fig. 1A) were internalized by HepG2
in a manner comparable to that of MV-HLSC (Fig. 1A).
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Figure 1. Incorporation of MV-HLSC in hepatoma cells inhibits proliferation and induces apoptosis. (A): PKH26-labeled MV-HLSC, or MV-
fibr, or MV-fibr-CD29 internalization in HepG2 detected by confocal microscopy in the presence or absence of blocking antibodies against a4
integrin, CD29, and CD44 and by fluorescence-activated cell sorting (FACS) analyses (filled curve: MV-HLSC internalization by HepG2). Kolmog-
rov-Smirnov statistical analyses of MVs versus Ctrl: p < .001. Three experiments were performed with similar results. Scale bar ¼ 10 lm.
(B): Analysis of HepG2 (black columns) and hepatocellular carcinoma cell (HCC [gray columns]) proliferation by BrdU internalization after 48
hours in the presence of vehicle alone (vehicle) or of different doses of MV-HLSC, MV-fibr, or MV-fibr-CTR, or MV-fibr-CD29, or MV-RNase.
Proliferation was evaluated on normal human Hep (blue columns) in the presence of vehicle alone or of MV-HLSC. (C): Analysis of HepG2 (black
columns) and HCC (gray columns) apoptosis by terminal dUTP nickend labeling assay (TUNEL) assay. Cells were incubated with vehicle, vincris-
tine, or different doses of MV-HLSC, or MV-fibr, or MV-fibr-CTR, or MV-fibr-CD29, or MV-RNase. Results in (B) and (C) are expressed as
mean 6 SD of six different experiments. (B and C): *, p < .05 versus vehicle; §, p < .05 versus MV-HLSC treatments. (D): Apoptosis of HepG2
coincubated with MV-HLSC and vincristine or Doxo was evaluated. To analyze the antiapoptotic effect of MV-HLSC on normal human Hep (blue
columns), apoptosis was induced by 5 mM GalN. Results are expressed as mean 6 SD of six different experiments. *, p < .05 versus vehicle; §, p
< .05 versus MV-HLSC, vincristine or Doxo alone; #, p < .05 versus Hep; þ, p < .05 versus HepþGalN. Abbreviations: BrdU, 5-bromo-2-deoxy-
uridine; Doxo, doxorubicin; GalN, D-galactosamine; Hep, hepatocytes; HLSC, human adult liver stem cell; MV, microvesicles; MV-HLSC, HSLC-
derived MV; MV-fibr, MVs derived from fibroblasts; MV-fibr-CD29, MVs derived from transfected fibroblasts overexpressing the CD29; MV-
RNase, RNase-inactivated MVs.
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However, the enhanced internalization of MV-fibr-CD29
did not affect HepG2 cell proliferation and apoptosis
(Fig. 1B, 1C).
When MV-HLSC were treated with high, unphysiological
concentration of RNase, that was previously shown to degrade
the MV-shuttle RNA [23] without affecting their structure
(Supporting Information Fig. 1B), the effect of MV-HLSC on
proliferation and apoptosis of HepG2 and HCC cell lines was
significantly reduced (Fig. 1B, 1C). These results suggest that
the biological effects of MV-HLSC on HepG2 were mediated
by the transfer of RNAs.
MV-HLSC Reduced In Vivo Growth of HepG2
Tumors in SCID Mice
When injected subcutaneously in SCID mice, HepG2 formed
tumors that became palpable after 1 week. Tumor growth was
monitored for 4 weeks. Treatment with HLSC-derived MVs
was started after 1 week by direct injection within the tumor
of 100 lg of MVs in a volume of 20 ll weekly for 3 weeks.
As shown in Figure 2 A and 2B, the increase in size and
weight of HepG2 tumors was significantly reduced in mice
injected with MV-HLSC with respect to controls injected
with vehicle alone (HepG2) or to mice injected with RNase-
inactivated MVs (MV-RNase) (Fig. 2A–2C). To evaluate the
role of CD29 in MV internalization by HepG2, in selected
experiments, we pretreated MVs with anti-human CD29
blocking antibody (MV-CD29). The CD29 blockade abro-
gated the in vivo effects mediated by MVs (Fig. 2A–2C). The
proliferation of HepG2 within the tumor mass detected by
PCNA, was significantly reduced in MV-HLSC treated tumors
with respect to control mice injected with vehicle alone, with
MV-RNase or with MV-CD29 (Fig. 2D; Supporting Informa-
tion Fig. 2A). Apoptosis detected by TUNEL was signifi-
cantly enhanced in mice treated with MV-HLSC with respect
to controls injected with vehicle alone or to mice injected
with MV-RNase or with MV-CD29 (Fig. 2E; Supporting
Information Fig. 2B).
Role of MV-Shuttled miRNAs in the Antitumor
Activity of MV-HLSC
We recently demonstrated the presence of enriched miRNAs
in MVs released by HLSC [10]. Among miRNAs present in
MV-HLSC, we detected several miRNAs with potential anti-
tumor activity including miR451, miR223, miR24, miR125b
miR31, and miR122 (Fig. 3A). Some of these miRNAs were
significantly enriched in MV-HLSC with respect to their rela-
tive HLSC suggesting a specific compartmentalization within
MVs. Moreover, these miRNAs were not detectable or were
expressed at low levels in HepG2 (Fig. 3A). On the contrary,
miR21 was not enriched in MV-HLSC but downregulated
with respect to HepG2. The levels of different miRNAs rela-
tive to each other in MV-HLSC are shown in Supporting
Information Figure 1D.
To investigate whether MVs may transfer miRNAs to tar-
get cells, HepG2 were incubated with MV-HLSC in the pres-
ence of a-amanitin to inhibit transcriptional activation. The
transfer of selected miRNAs was evaluated by qRT-PCR. The
variation in cycle threshold (Ct) values in HepG2 stimulated
with MV-HLSC in the presence of a-amanitin was evaluated
with respect to HepG2 treated with a-amanitin alone. The
accumulation of miRNAs into HepG2 treated with MVs
peaked after overnight stimulation (16 hours) to decrease at
24 hours (Fig. 3B). The miR-410, not present in MV-HLSC
and used as a negative control, was not detected in HepG2
after MV incorporation. This suggested that the increase in
specific miRNA content was due to their transfer from MVs
to the HepG2. MVs from fibroblasts, used as control, con-
tained significant less amount of tumor suppressive miR451,
223, and 31, than MV-HLSC (Fig. 3C).
The RNA shuttled by MVs into HepG2 was also eval-
uated in vivo. MVs isolated from HLSC labeled with SYTO
RNA dye that tagged cell RNA were then stained with
PKH26 and injected intratumor. The analysis of excised
tumors showed the colocalization of both dyes, suggesting the
incorporation of RNA-containing MV into HepG2 tumors
(Fig. 3D).
To evaluate whether miRNAs shuttled by MV-HLSC
were relevant for the tumor suppression, we generated MVs
from Dicer knockdown HLSC (DCR-Kd HLSC). As shown in
Figure 4A, Dicer was selectively downregulated at mRNA
and protein levels in DCR-Kd HLSC but not in scramble
transfected control HLSC (CTR-A HLSC). The specificity of
downregulation of Dicer was indicated by the unaltered
expression of the Argonaute 2 transcript. MVs released from
DCR-Kd HLSC (MV DCR), but not from CTR-A HLSC
(MV CTR-A), showed a significant reduction of miR223,
miR24, miR31, miR122, and miR214 as detected by qRT-
PCR (Fig. 4B). No modulation in miR21 and miR125b levels
was observed.
As shown in Figure 4C, MVs derived from DCR-Kd
HLSC, but not from CTR-A HLSC, exhibited a significant
reduction of the in vitro proapoptotic effect on HepG2. More-
over, the incubation of HepG2 with MVs derived from HLSC
resulted in the reduction of proteins known to be targeted by
some of the enriched miRNAs found in MV-HLSC (Fig. 4D).
In particular, the following target proteins, involved in cell
proliferation, were downregulated: DHFR targeted by miR24
[33], Cyclin D1 targeted by miR223 [34], and E2F-2 targeted
by miR31 [35]. Moreover, the following target proteins,
involved in resistance to apoptosis were downregulated: BCL-
XL, targeted by miR122, BCL-2, targeted by miR122 [36],
and in less extent XBP-1, targeted by miR214 [37]. No down-
regulation of proteins involved in cell proliferation and apo-
ptosis resistance was observed on normal human hepatocytes
treated with MV-HLSC (Fig. 4D). Actin was used as control.
MV DCR, but not MV CTR-A, did not induce downregula-
tion of these target proteins. In addition, MV DCR did not
significantly inhibit the growth of HepG2 tumors in SCID
mice (Fig. 4E, 4F).
In Vitro Biological Effect of Specific
miRNA Inhibitors
To evaluate whether single miRNAs with antitumor activity
(miR451, miR223, miR24, miR125b, and miR31) were rele-
vant for the proapoptotic effect of MV-HLSC, we transfected
HepG2 with selected miRNA inhibitors (Fig. 5A). HepG2
transfected with a negative control miRNA inhibitor (anti-
CTR) did not differ from HepG2 wild-type in sensitivity to
apoptosis induced by MV-HLSC. In contrast, HepG2 trans-
fected with selected miRNA inhibitors exhibited a significant
reduction of sensitivity to apoptosis induced by MVs (Fig.
5A). This was more significant for miR451, miR223, and
miR31. The observation that blockade of individual miRNAs
completely abrogated, or significantly reduced, the effect of
MV-HLSC suggest that each of these miRNA is a critical
component of the puzzle that controls cell proliferation and
survival. HepG2 transfection with miR451, miR31, and
miR223 mimics, which reproduce mature endogenous miR-
NAs, inhibited proliferation of HepG2 (Fig. 5B). The miR451
mimic mediated also a proapoptotic effect comparable to that
of MV-HLSC (Fig. 5C). In particular, we analyzed the
involvement in MV-HLSC antitumor activity of miR31 and
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miR451, previously described as regulators of proliferation
and as tumor suppressors in different cancer cells [35, 38,
39]. As shown in Figure 5D, MDR1, targeted by miR451
[40], was strongly expressed on HepG2 cell membrane. After
incubation with MV-HLSC, the expression of MDR1 was
markedly reduced (Fig. 5D). When HepG2 were transfected
with the miRNA inhibitor, anti-miR451, MVs were unable to
downregulate the MDR1 expression, suggesting that miR451
transferred by MVs was biologically active. Transfection with
the negative control miRNA inhibitor (anti-CTR) was ineffec-
tive. Transfection of HepG2 with anti-miR451 without MV
treatment, did not affect MDR1 expression (data not shown).
We also observed that the HepG2 stimulation with MV-HLSC
induced a downregulation of two other important miR451 tar-
gets, MIF and RAB14 (Fig. 5D) [40, 41]. Their downregula-
tion, induced by MVs, was abrogated when HepG2 were
transfected with anti-miR451, but not with anti-CTR (Fig.
5D). Similar results were observed for E2F-2 which is tar-
geted by miR31 (Fig. 5E). Furthermore, HepG2 transfection
with miR451 and miR31 mimics resulted in MDR1, MIF,
RAB14, and E2F-2 downregulation similar to that of MV-
HLSC (Fig. 5D, 5E).
The potential relevance of miRNA transfer from HLSC to
HepG2 was outlined by the observation that miRNAs with
antitumor activity are slightly or not detectable in HepG2
whereas they are highly expressed in normal human hepato-
cytes (Supporting Information Fig. 3A). On the contrary,
miR21, known to act as oncomiR in different tumors [41],
was more expressed in HepG2 than in normal human hepato-
cytes. The differences in miRNA expression were paralleled
by a difference in the expression of their specific targets. Sup-
porting Information Figure 3B shows that MDR1, MIF, and
RAB14, targeted by miR451, and E2F-2, targeted by miR31,
were overexpressed at RNA level in HepG2 with respect to
hepatocytes. As shown in Figure 3C, the content of tumor-
suppressive miRNAs miR451, 223, and 31, in MVs from
fibroblast used as control was significantly lower than that
of MV-HLSC. Treatment of MV-HLSC with high concentra-
tion of RNase (5 U/ml) significantly decreased the levels of
different miRNAs shuttled by MVs (Supporting Information
Fig. 1C).
In Vivo Biological Effect of Anti-miR451
or Anti-miR31 Inhibitors
The in vivo potential involvement of miR451 and miR31 was
evaluated by intratumor administration of anti-miR451 or
anti-miR31 or of negative control anti-CTR 24-hour before
the administration of MV-HLSC. Experiments performed with
a ter 6-carboxyfluorescein (FAM) labeled negative control
Figure 2. In vivo antitumor effect of MV-HLSC. (A): Tumor growth in SCID mice injected subcutaneously with 3  106 HepG2 and after 1 week
treated weekly with vehicle (^, HepG2) or 100 lg of MV-HLSC (h), with MV-RNase (~) or with CD29 blocking antibody-treated MV-HLSC (*,
MV-CD29). (B): Tumor weights after excision from severe combined immunodeficiency (SCID) mice at sacrifice. Results are expressed as mean 6
SD of 12 mice for experimental group. *, p < .05 versus HepG2; §, p < .05 versus MV-HLSC. (C): Representative micrographs of H&E staining of
tumor sections from SCID mice treated with vehicle alone (HepG2) or with MV-HLSC, MV-RNase, and MV-CD29. Large areas of necrosis were visi-
ble in tumors treated with MV-HLSC. Scale bar ¼ 50 lm. (D): Quantification of Proliferating Cell Nuclear Antigen (PCNA)-positive cells/hpf was cal-
culated. (E): Quantification of apoptotic cells/hpf was calculated. Data are expressed as mean 6 SD of 12 mice for experimental group. *, p < .05
versus HepG2; §, p < .05 versus MV-HLSC. Abbreviations: HLSC, human adult liver stem cells; hpf, high power field; MV, microvesicles; MV-
HSLC, HSLC-derived MV; MV-RNase, RNase-inactivated MVs; MV-CD29, MVs pretreated with anti-CD29 blocking antibody.
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miRNA inhibitor showed that the intratumor injection is fol-
lowed by its internalization within the cells (not shown). In
mice treated with anti-miR451 and anti-miR31, the inhibition
of tumor growth induced by MV-HLSC was significantly less
effective than in animals treated with anti-CTR (Fig. 6, A–
6C). We observed a reduced apoptosis in tumors treated with
MV-HLSC in the presence of the selected anti-miRNAs (anti-
miRs) with respect to tumors treated with MVs in the pres-
ence of anti-CTR (Fig. 6D). MDR1, MIF, RAB14, and E2F-2
were highly expressed by HepG2 tumors in vivo as detected
by immunofluorescence (Fig. 6E, 6F). MV treatment downre-
gulated the in vivo expression of these target proteins. The in-
hibitory effect of MV-HLSC was abrogated by anti-miR451
and anti-miR31 administration (Fig. 6E, 6F). Treatment with
anti-miR451 and anti-miR31 in the absence of MVs did not
interfere with target expression by hepatoma tumors.
MV-HLSC significantly inhibited also the growth of
tumors induced in SCID mice by primary HCCs (Fig. 7A).
Figure 3. MV-mediated transfer of miRNAs with potential antitumor activity to HepG2. (A): The expression of miR451, miR223, miR24,
miR125b, miR31, miR21, miR122, and RNU48 was evaluated by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in
HLSC (gray bars) and MV-HLSC (white bars) with respect to HepG2. Data were expressed as log of Rq, normalized to GAPDH mRNA and to
one for HepG2. Some of these miRNAs were significantly enriched in MVs with respect to their relative human adult liver stem cell (HLSC) and
were less expressed or not detectable in HepG2. Data are the mean 6 SD of four experiments. *, p < .05 versus HepG2. (B): HepG2 were incu-
bated with HLSC-derived MV (MV-HLSC) 6 hours, overnight (ON, 16 hours), and 24 hours (h), and the transfer of selected miRNAs was eval-
uated by qRT-PCR. The difference in Ct values between HepG2 treated with vehicle or stimulated with MV-HLSC was shown for each miRNA.
The RNU48 and the miR410, that was not present in MVs, were used as controls. Data are the mean 6 SD of four experiments. (C): Relative
expression of miR451, miR223, and miR31 in MV-HLSC (white bar) with respect to MVs derived from fibroblasts (MV-fibr [gray bar])
evaluated by qRT-PCR. Data were normalized to GAPDH mRNA, to one for MV-fibr and expressed as mean 6 SD. Three experiments were
conducted with similar results. *, p < .05 versus MV-fibr. (D): Representative micrographs showing the in vivo internalization in tumors of MV-
HLSC labeled with PKH26 and SYTO RNA that stain MV membrane and RNA content, respectively. Three experiments were performed with
similar results. Abbreviations: miRNA, micro RNA; Rq, relative quantification.
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To evaluate whether the biological effect of MV-HLSC was
specific to hepatic tumors, we investigated also SupT1 lym-
phoblastoma and DBTRG-05MG glioblastoma cells (DBTRG)
injected subcutaneously in SCID mice. As shown in Figure 7,
MV-HLSC significantly inhibited SupT1 and DBTRG tumor
growth (Fig. 7A–7C). This was confirmed in vitro where
MVs inhibited proliferation and induced apoptosis of tumor
cells (Fig. 7D, 7E).
Figure 4. Effect of MVs derived from DCR-kd HLSC on in vitro HepG2 apoptosis and in vivo tumor growth. (A): Quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR) analysis of DCR1 and AGO2 transcripts in DCR-Kd (white bar) and CTR-A (gray bar). Western blot of Dicer pro-
tein expression (lower panel). Actin was used as endogenous control. *, p < .05 versus CTR-A. (B): Analysis of miRNAs in MV DCR (white bar) or
in MV CTR-A (gray bar) evaluated by qRT-PCR. *, p < .05 versus MV CTR-A. Data in (A) and (B) are representative of three different experiments.
Data were normalized to GAPDH mRNA and to one for CTR-A and MV CTR-A. (C): Analysis of HepG2 apoptosis by terminal dUTP nickend labeling
assay (TUNEL) assay. Cells were incubated with vehicle alone (HepG2), with 10 ng/ml vincristine, or with 30 lg/ml of MV CTR-A, MV DCR, or
control MV-HLSC. Results are expressed as mean 6 SD of five different experiments. *, p < .05 versus HepG2; #, p < .05 versus MV CTR-A. (D)
Expression of XBP-1, BCL-XL, BCL-2, DHFR, cyclin D1, E2F-2, and Actin was evaluated by Western blot in HepG2 treated with vehicle alone
(HepG2) or with 30 lg/ml of MV-HLSC, MV CTR-A, or MV DCR, and in human hepatocytes treated with vehicle alone (Hep) or with 30 lg/ml of
MV-HLSC. Three experiments were conducted with similar results. (E, F): HepG2 were injected subcutaneously in severe combined immunodeficiency
(SCID) mice and treated weekly with 100 lg of MV CTR-A or of MV DCR. Measure of tumor mass (E) and weight (F) was evaluated at sacrifice.
Results are expressed as mean 6 SD of five mice for experimental group. *, p < .05 versus MV CTR-A. Abbreviations: AGO2, Argonaute 2 transcript;
CTR-A, scramble transfected control HLSC; DCR1, Dicer 1; DCR-kd, Dicer knockdown; Hep, hepatocytes; HLSC, human adult liver stem cell; MV-
HLSC, HSLC-derived MV; MV CTR-A, MVs from CTR-A transfected HLSC; MV DCR, MVs from DCR-kd HLSC; Rq, relative quantification.
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Figure 5. Effect of specific microRNA (miRNA) inhibitors and of miRNA mimics on in vitro apoptosis and on modulation of target proteins.
(A): terminal dUTP nickend labeling assay (TUNEL) assay of HepG2 transfected with specific miRNA inhibitors and with anti-CTR inhibitor
and treated with MV-HLSC. Results are expressed as mean 6 SD of three different experiments. *, p < .05 versus anti-CTR alone; #, p < .05
versus anti-CTRþMV-HLSC. (B): The antiproliferative effect of MV-HLSC on HepG2 was compared with the effect of miR451, miR223, and
miR31 mimics by 5-bromo-2-deoxyuridine incorporation. (C): The proapoptotic effect of miR451 mimic on HepG2 was evaluated by TUNEL
assay and compared with that of MV-HLSC and vincristine. Results are expressed as mean 6 SD of six different experiments. *, p < .05 versus
SCR. (D): Representative micrographs showing the downregulation of MDR1, MIF, and RAB14 targeted by miR451 in HepG2 incubated with
MV-HLSC or transfected with mimic 451. Transfection of HepG2 with anti-miR451 (anti-miR451þMV) but not with anti-CTR abrogated the tar-
get downregulation induced by MV-HLSC. (E): Representative micrographs showing the downregulation of E2F-2 targeted by miR31 in HepG2
incubated with MV-HLSC or transfected with mimic 31. Transfection of HepG2 with anti-miR31 (anti-miR31þMV) abrogated the E2F-2 down-
regulation induced by MV-HLSC. Experiments were repeated three times with similar results. Scale bar ¼ 10 lm. Abbreviations: Anti-CTR, neg-
ative control miRNA; CTR, control; MV-HLSC, HLSC derived microvesicles; MDR, multidrug resistance protein 1; RAB14, ras-related protein
14; MIF, migration inhibitory factor; SCR, negative control siRNA transfected HepG2.
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Figure 6. Effect of specific microRNA inhibitors on MV-induced inhibition of tumor growth and on modulation of target proteins. (A–D): Tumor growth
in severe combined immunodeficiency (SCID) mice injected subcutaneously with 3  106 HepG2 and treated weekly with vehicle (n, HepG2) or with 100
lg of MV-HLSC in the presence of anti-miR31 (^) or anti-miR451 (h) or anti-CTR (~). Tumor mass was determined weekly by caliper (A) and by mea-
sure of tumor size (B) and weight (C) at sacrifice. (D): Apoptotic cells within the tumors were evaluated by terminal dUTP nickend labeling assay (TUNEL)
assay. Results in (B–D) are expressed as mean 6 SD of six mice for experimental group. *, p < .05 versus HepG2; §, p < .05 versus anti-CTRþMV-
HLSC. (E): Representative micrographs showing the in vivo expression of MDR1, MIF, and RAB14 in HepG2, the downregulation of targets by MV-
HLSC (anti-CTRþMV), and the abrogation of downregulation by anti-miR451 treatment (anti-miR451þMV). Treatment with anti-miR451 without MV
administration (anti-miR451) did not interfere with protein expression by HepG2. (F): Representative micrographs showing the in vivo expression of E2F-2
in HepG2, its downregulation by MV-HLSC treatment in the presence of anti-CTR inhibitor (anti-CTRþMV), and the abrogation of downregulation by anti-
miR31 (anti-miR31þMV). Treatment with anti-miR31 without MV administration (anti-miR31) did not interfere with E2F-2 expression by HepG2. Micro-
graphs are representative of six different experiments. Scale bar ¼ 10 lm. Abbreviations: anti-CTR, negative control miRNA; HLSC, human adult liver
stem cell; MV-HLSC, HLSC derived MV; MDR, multidrug resistance protein 1; RAB14, ras-related protein 14; MIF, migration inhibitory factor.
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DISCUSSION
The results of this study demonstrated that MVs released from
HLSC inhibited the growth of hepatoma cells both in vitro and
in vivo. We suggest that the mechanism is related to the deliv-
ery of miRNAs from MV-HLSC to tumor cells on the basis of
the following evidence: (a) the rapid, CD29-mediated internal-
ization of MVs in tumor cells and the inhibition of their growth
after MV uptake; (b) the transfer of antitumor MV-HLSC miR-
NAs that were downregulated in HepG2 cells with respect to
normal hepatocytes; (c) the abrogation of the MV-HLSC anti-
tumor effect after the MV pretreatment with RNase, Dicer
silencing in HLSC, and the transfection of HepG2 with specific
miRNA inhibitors; (d) finally, the relevance of selected miR-
NAs as proven by transfecting HepG2 with miRNA mimics.
MVs/exosomes have been recently described as new
mediators of cell-to-cell communication that may reprogram
the target cells through the active transfer of proteins, func-
tional mRNAs, and miRNAs [13]. In particular, the finding
that MVs may carry selected patterns of mRNAs and miR-
NAs have suggested their involvement in genetic exchange
among cells [22, 23, 25, 26]. As stem/progenitor cells are an
abundant source of MVs, it is conceivable that they play a
role in stem cell biology [42, 43]. Stem cell-derived MVs are
enriched in miRNAs that can be transferred to other cells.
The biological effects of such miRNAs may be different
depending on the genetic state of the recipient cells. miRNA
expression is known to be deregulated in tumors [44]. In par-
ticular, it has been shown a downregulation of miRNAs with
tumor suppressor activity and an upregulation of miRNAs
that may act as oncogenes [45–47].
In this study, we evaluated whether MV-HLSC may influ-
ence the in vitro behavior of HepG2 cells and of primary HCC
cells. It is now recognized that upon release MVs may be inter-
nalized in target cells through specific receptor–ligand interac-
tions allowing the transfer of specific signals [9]. When incubated
with HepG2 or HCC cells, labeled MVs were rapidly internal-
ized. In particular, we demonstrated that the adhesion molecule
mainly involved in MV uptake by hepatoma cells was the CD29.
Indeed, the CD29 blockade inhibited the MV internalization by
tumor cells. The uptake of MV-HLSC by HepG2 and HCC cells
in vitro resulted in a significant inhibition of tumor cell growth
and stimulation of apoptosis. In vivo treatment with MV-HLSC
significantly reduced the growth of HepG2 tumors formed in
SCID mice by enhancing tumor apoptosis and reducing
Figure 7. In vitro and in vivo effect of human adult liver stem cell-derived microvesicle (MV-HLSC) on HCC hepatocarcinoma, SupT1 lympho-
blastoma, and DBTRG glioblastoma cells. (A): Tumor growth in severe combined immunodeficiency (SCID) mice injected subcutaneously with 3 
106 HCC (n green), SupT1 (n red), or DBTRG (n blue) and treated weekly with vehicle or 100 lg of MV-HLSC (HCC ¼ ~ green, SupT1 ¼ ~
red, and DBTRG ¼ ~ blue). Measure of tumor mass (B) and tumor weight (C) excised from SCID mice treated with vehicle alone (black bars) or
with MV-HLSC (white bars) at sacrifice. Results are expressed as mean 6 SD of four mice for experimental group. *, p < .05 versus vehicle alone.
Effect of MV-HLSC (30 lg/ml) on in vitro proliferation evaluated by BrdU incorporation (D) and on apoptosis evaluated by TUNEL (E) of HepG2,
SupT1, and DBTRG. Vincristine was used as positive control of apoptosis (gray bar). Results in (D) and (E) are expressed as mean 6 SD of six
individual experiments. *, p < .05 versus vehicle alone. Abbreviations: BrdU, 5-bromo-2-deoxyuridine; HCC, hepatocellular carcinoma cell.
Fonsato, Collino, Herrera et al. 1995
www.StemCells.com
proliferation. When MV-HLSC were pretreated with a CD29
blocking antibody, the antitumor effect was abrogated, suggest-
ing a role of surface molecules in the MV uptake by target cells.
We previously suggested that the biological effects observed
on normal cells could be ascribed to the transfer by MVs of
selected patterns of mRNAs and miRNAs able to activate
regenerative programs [9, 10]. This interpretation is strength-
ened by several other studies that demonstrated that the genetic
information transferred by MVs is the main effector of func-
tional and phenotypical changes occurring in recipient cells [10,
25, 26, 48]. Here, MV-HLSC slightly stimulated proliferation
and protected from apoptosis normal human hepatocytes at var-
iance with hepatoma cells. The discrepancy in behavior between
normal and tumor cells is possibly due to the differential activa-
tion of their intracellular pathways. It is well-established that tu-
mor cells are deficient of several miRNAs relevant in the con-
trol of cell growth [44]. This is confirmed in our experimental
setting by a qRT-PCR comparative analysis of miRNA expres-
sion between HepG2 and normal human hepatocytes.
Here, we observed that the antitumor effect of MV-HLSC
was mainly dependent on the transfer of selected miRNAs.
Therefore it can be hypothesized that MVs released from
HLSC may deliver to HepG2 miRNAs able to reprogram
these cells to a more benign phenotype both in vitro and in
vivo. Among miRNAs present in MV-HLSC [10], several
ones were associated with potential antitumor activity, such
as miR451, miR223, miR24, miR125b, miR31, miR214, and
miR122. Some of these miRNAs were not or only slightly
detectable in HepG2 at variance of normal hepatocytes.
Experiments with RNase treatment indicated that a deple-
tion of miRNAs shuttled by MVs was associated with a
reduced biological activity both in vitro and in vivo. The rele-
vance of miRNA transfer to HepG2 via MVs was also derived
from experiments with MVs obtained from HLSC knockdown
for Dicer1, which is critical for the maturation of miRNAs
[49–51]. Previous studies of Dicer depletion in mouse embry-
onic stem cells demonstrated a role of miRNAs in stem cell
differentiation and self-renewal capability [52, 53]. Further-
more, Oskowitz et al. recently showed that the miRNA
processing machinery is also involved in the osteogenic and
adipogenic differentiation of adult human MSC [54].
Silencing Dicer in HLSC resulted in the modulation of
different miRNAs, with a significant reduction of the antitu-
mor miR223, miR24, miR31, and miR122 [55] in MVs. The
MV DCR isolated from DCR-Kd HLSC showed a signifi-
cant reduction of the in vitro proapoptotic activity and the in
vivo antitumor effect.
Specific target proteins involved in cell cycle control,
were downregulated in HepG2 treated with MV-HLSC. Inter-
estingly, these proteins were targeted by miRNAs present in
MV-HLSC and reduced in MV DCR. When HepG2 were
treated with MV DCR, the reduction of such targets was
absent. These experiments indicate that miRNAs shuttled by
MV-HLSC were functionally intact.
Moreover, the use of miRNA inhibitors against miR451,
miR223, miR24, miR125b, and miR31 on HepG2 reduced the
proapoptotic activity induced by MV-HLSC. The most con-
vincing results were obtained with inhibitors of miR31 and 223
that were downregulated also in MV DCR as well as with the
inhibitor of miR451, that has been previously described as a
Dicer independent miRNA [56]. Moreover, the miR451 has
been shown to regulate drug resistance to chemotherapeutics
mediated by MDR1/P-glycoprotein [41]. MV treatment
induced a reduction of MDR1 surface expression in HepG2.
This observation may explain our results showing a combina-
tory effect of MV-HLSC and chemotherapeutic agents in the
enhancement of apoptosis. HepG2 stimulation with MV-HLSC
induced a downregulation of MIF and RAB14, previously
shown to be important miR451 targets [39, 40]. The downregu-
lation of miR451 target proteins, induced by MV-HLSC, was
abrogated when HepG2 were transfected with anti-451 miRNA
inhibitor. Similar results were observed for E2F-2, which is tar-
geted by miR31 [38], indicating the relevance of these miR-
NAs in the antitumor activity of MVs. The prominent role of
miR451 and miR31 transfer was indicated by the direct antitu-
mor activity of miR451 and miR31 mimics on HepG2 that
resulted in MDR1, MIF, RAB14, and E2F-2 downregulation
similar to that of MV-HLSC. Of interest, MDR1, MIF,
RAB14, and E2F-2 proteins were overexpressed in HepG2
with respect to normal human hepatocytes.
The antitumor effect was specific of MV-HLSC since the
MVs from fibroblast were ineffective. This could depend on a
reduced internalization, due to absence of CD29 on MV-fibr or
on a reduced expression of antitumor miRNAs. However, when
MV-fibr expressing CD29 were used, the enhanced internaliza-
tion was not associated with an enhanced biological activity.
Therefore, it is likely that the different composition of miRNA
content between MV-HLSC and MV-fibr was the main cause
of the different biological action. On the other hand, the effect
of MV-HLSC was not confined to hepatic tumors as they were
effective also on lymphoblastoma and glioblastoma tumors.
CONCLUSIONS
In conclusion, the results of this study suggest that MVs derived
from HLSC may inhibit the growth of hepatoma tumors by
transferring genetic information that interferes with the deregu-
lated survival and proliferation of these cells. This biological
effect could be ascribed to specific miRNAs shuttled by MV-
HLSC that are able to modulate signaling pathways differentially
activated in tumor cells in respect to normal cells. Therefore, one
can speculate that the specificity of biological signal triggered by
stem cell-derived MVs depends on the recipient cells and not
only on the genetic information transferred by the cell of origin.
These results have possible implication on the development of a
therapeutic strategy based on MV-mediated delivery of miRNAs
[57] present in normal stem cells but not in tumor cells.
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